.
Search
Dr. Richard Wright and Dr. C. Michael Gibson discuss the first peer-reviewed, real-world comparative effectiveness study of TTR stabilizers using U.S. claims data. Acoramidis was associated with a 34% lower risk of clinical worsening and a 43% lower risk of diuretic intensification compared with tafamidis.
Sponsored by an independent educational grant from BridgeBio Inc.
Dr. Jim Januzzi and Dr. C. Michael Gibson discuss the findings from the randomized controlled ATTRIBUTE-CM trial examining the relationship between these biomarkers and clinical outcomes in transthyretin amyloid cardiomyopathy.
Sponsored by an independent educational grant from BridgeBio Inc.
Dr. Kevin Alexander and Dr. C. Michael Gibson discuss: Durable Survival Benefits of Acoramidis over 54Months in Variant Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Includingp.V142I: Interim Findings from ATTRibute-CM and its Open-Label Extension
Sponsored by an independent educational grant from BridgeBio Inc.